SATOn tilinpäätöstiedote 2023: Haastava vuosi – asiakastyytyväisyys parani
09 févr. 2024 02h00 HE
|
SATO Oyj
SATO Oyj, Pörssitiedote 9.2.2024 klo 9.00Yhteenveto ajalta 1.1.-31.12.2023 (1.1.-31.12.2022) Taloudellinen vuokrausaste heikkeni ja oli 94,9 % (95,2).Liikevaihto oli 288,4 milj. €...
SATO Corporation’s Financial Statements Bulletin 2023: Challenging year – customer satisfaction improved
09 févr. 2024 02h00 HE
|
SATO Oyj
SATO Corporation, Stock Exchange Release 9 February 2024 at 9:00 am Highlights January–December 2023 (January–December 2022) The economic occupancy rate decreased and was 94.9% (95.2).Net sales...
EPI Health, a Novan Company, Enters into Exclusive License Agreement with Sato Pharmaceutical Co., Ltd. for RHOFADE® in Japan
21 déc. 2022 08h00 HE
|
Novan, Inc.
DURHAM, N.C., Dec. 21, 2022 (GLOBE NEWSWIRE) -- Novan, Inc. (“the Company” or “Novan”) (Nasdaq: NOVN), today announced that EPI Health, LLC, a fully consolidated subsidiary of Novan, has entered...
Novan Receives Verbal Guidance from FDA for SB206 and Announces Sato Program Advancement
03 avr. 2020 08h15 HE
|
Novan, Inc.
Per verbal guidance, FDA to consider one additional pivotal trialFDA-generated minutes expected on or before May 1, 2020Sato Pharmaceutical to begin start-up of Phase 1 trial in Japan MORRISVILLE,...
SATO Goes Further Beyond Expectations with Refresh of Universal Industrial Thermal Printer Line
14 janv. 2020 07h00 HE
|
SATO America
Tokyo, Jan. 14, 2020 (GLOBE NEWSWIRE) -- Tokyo, January 14, 2020 – SATO, a global pioneer in the development of auto-ID and labeling solutions today launched CL4NX Plus, a best in class thermal...
Novan and Sato Advance Japan Market and Dermatology Partnership
19 mars 2019 09h00 HE
|
Novan, Inc.
Dr. Elizabeth Messersmith named chairperson of the Sato and Novan Joint CommitteeSimultaneous clinical development progress for SB206 in Japan and US underwayNovan receives second installment of $4.5...
Novan Expands Nitric Oxide Dermatology Business Partnership with Sato in Japan
08 oct. 2018 08h00 HE
|
Novan, Inc.
Expanded license agreement adds SB206 for the treatment of viral skin infections Novan to receive upfront cash consideration of approximately 1.25 billion JPY (~$11.0 million), payable over the next...
Novan Licenses SB204 to Sato for Acne in Japan
17 janv. 2017 09h05 HE
|
Novan, Inc.
MORRISVILLE, N.C., Jan. 17, 2017 (GLOBE NEWSWIRE) -- Novan, Inc. (“the Company” or “Novan”) (NASDAQ:NOVN) today announced that the Company has entered into an exclusive license agreement with Sato...
Omni-ID Adds SATO as Strategic Partner to Create a Certified Omni-ID On Demand Solution
07 avr. 2009 09h00 HE
|
Omni-ID
FOSTER CITY, CA--(Marketwire - April 7, 2009) -
Omni-ID, a leading innovator in
passive ultra high frequency (UHF) radio frequency identification (RFID)
technology, today announces it has...